$SGP News

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space

Raymond James Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $39

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate

SpyGlass Pharma shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

SpyGlass Pharma shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY

HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment

SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

Citigroup Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42